{"id":8714,"date":"2025-10-06T15:36:00","date_gmt":"2025-10-06T13:36:00","guid":{"rendered":"https:\/\/eqegttw.cluster100.hosting.ovh.net\/?p=8714"},"modified":"2026-02-03T17:11:48","modified_gmt":"2026-02-03T16:11:48","slug":"obesity-in-france-evolving-care-pathways-innovations-and-market-perspectives","status":"publish","type":"post","link":"https:\/\/www.aplusaresearch.com\/fr\/perspectives\/obesity-in-france-evolving-care-pathways-innovations-and-market-perspectives\/","title":{"rendered":"L'ob\u00e9sit\u00e9 en France : \u00c9volution des parcours de soins, innovations et perspectives de march\u00e9"},"content":{"rendered":"\n
Obesity has become a major public health issue in France. It currently affects more than 8 million individuals, and prevalence continues to rise. Projections estimate that nearly 20 million French citizens could be living with obesity by 2030 [1].<\/p>\n\n\n\n
Once regarded merely as a lifestyle concern, obesity is now recognized as a complex chronic disease. However, in France, this institutional recognition remains incomplete: the absence of official ALD (Affection Longue Dur\u00e9e) status restricts treatment reimbursement and hampers the development of a coordinated care pathway.<\/p>\n\n\n\n
Obesity in France: an under-recognized chronic disease<\/h2>\n\n\n\n
\n
\n
<\/figure>\n<\/div>\n\n\n\n
\n
Despite its growing prevalence, obesity is still not fully integrated into chronic disease management frameworks in France. This delay directly affects access to innovative treatments and the structuring of care pathways. For the pharmaceutical industry, this context creates both market opportunities and regulatory challenges.<\/p>\n<\/div>\n<\/div>\n\n\n\n
The patient voice and expectations regarding obesity treatments<\/h2>\n\n\n\n
During the Breakfast Briefing organized by APLUSA, patients expressed a mixture of hope and frustration. They demonstrated strong interest in innovative obesity therapies, such as GLP-1 receptor agonists, which are perceived as more effective than conventional diets.<\/p>\n\n\n\n
Nevertheless, several barriers remain: high treatment costs, frequent supply shortages, and administrative burdens [8,10].<\/p>\n\n\n\n
\u201cI have tried every diet. For the first time, a treatment is delivering real results\u2026 but I have no guarantee that I will be able to continue.\u201d Patient, APLUSA Obesity Breakfast Briefing 2025<\/p>\n\n\n\n
These insights highlight the importance of integrating the patient perspective into development strategies and market access planning.<\/p>\n\n\n\n
Pharmacological innovations in obesity: GLP-1 and multi-agonists<\/h2>\n\n\n\n
GLP-1 receptor agonists and emerging multi-agonists (tirzepatide, retatrutide, cagrilintide + semaglutide) represent a therapeutic breakthrough. Clinical trials report unprecedented weight reduction outcomes ranging from -12% to -24% [3\u20137].<\/p>\n<\/div>\n<\/div>\n\n\n\n
While these innovations open significant opportunities for the obesity pharmaceutical market, they also raise critical questions about reimbursement access and economic sustainability.<\/p>\n\n\n\n
Obesity care pathways in France: current status<\/h2>\n\n\n\n
The obesity care pathway remains fragmented and under-resourced. The 37 Specialized Obesity Centers (CSO) treat only 20,000 patients annually [9]. Although 70% of patients discuss obesity with their physician, only 24% receive a structured treatment plan [8]. Furthermore, fewer than 15% of patients followed in CSOs have access to psychological support [12].<\/p>\n\n\n\n
This situation underscores the need for a comprehensive, multidisciplinary approach involving primary care, hospital-based specialists, and psychological support.<\/p>\n\n\n\n
Economic impact of obesity: a challenge for public health and the pharmaceutical industry<\/h2>\n\n\n\n
\n
\n<\/figure>\n<\/div>\n\n\n\n
\n
The cost of obesity in France is estimated at \u20ac12.7 billion in 2024 and could rise to \u20ac15.4 billion by 2030 [2]. At the OECD level, obesity accounts for 3.3% of GDP [13].<\/p>\n\n\n\n
For pharmaceutical companies, these figures reflect both the scale of unmet needs and the opportunity to contribute to reducing this burden through innovative therapeutic solutions.<\/p>\n<\/div>\n<\/div>\n\n\n\n
International benchmarks: lessons for France from the U.S. and Denmark<\/h2>\n\n\n\n
\n
United States: rapid uptake of GLP-1 therapies, but marked by significant disparities in access [14].<\/li>\n\n\n\n
Denmark: a national strategy combining progressive reimbursement and school-based prevention, with measurable impact on diabetes incidence [15].<\/li>\n\n\n\n
HIV experience: the success of triple therapy and expanded access to PrEP illustrate the transformative potential of collective mobilization [16].<\/li>\n<\/ul>\n\n\n\n
These international experiences demonstrate that success relies on an integrated strategy combining market access, prevention, and patient support.<\/p>\n\n\n\n
APLUSA: a strategic partner for pharmaceutical companies<\/h2>\n\n\n\n
APLUSA leverages the patient voice to generate strategic insights, maps real-world care pathways using RWE (Real-World Evidence) and HEOR (Health Economics and Outcomes Research) data, and supports pharmaceutical companies in preparing market access and reimbursement dossiers. Our expertise enables healthcare stakeholders to better understand the pharmaceutical obesity market and anticipate its evolution.<\/p>\n\n\n\n
Conclusion: transforming obesity into a collective public health success<\/h2>\n\n\n\n
Obesity in France stands at a pivotal moment. Pharmacological innovation and international benchmarks demonstrate that success depends on collective mobilization, bringing together patients, healthcare professionals, policymakers, and the pharmaceutical industry. It is time to make obesity the next major public health success story.<\/p>\n\n\n\n
FAQ \u2013 Obesity and the pharmaceutical market<\/h2>\n\n\n\n
What new obesity treatments are currently available in France?<\/h3>\n\n\n\n
GLP-1 receptor agonists such as Wegovy (semaglutide) and Mounjaro (tirzepatide) are already marketed. Other molecules, including retatrutide and CagriSema, are currently in Phase 3 clinical trials.<\/p>\n\n\n\n
What is the economic cost of obesity in France?<\/h3>\n\n\n\n
The direct and indirect cost of obesity is estimated at \u20ac12.7 billion in 2024 and could reach \u20ac15.4 billion by 2030.<\/p>\n\n\n\n
Is obesity recognized as a chronic disease in France?<\/h3>\n\n\n\n
Yes, but only partially. The absence of official ALD status currently limits reimbursement and coordinated care pathways.<\/p>\n\n\n\n
What role does APLUSA play in obesity care and market access?<\/h3>\n\n\n\n
APLUSA supports pharmaceutical companies through market research, patient pathway analysis (RWE\/HEOR), and preparation of market access and reimbursement submissions.<\/p>\n\n\n\n
References<\/h2>\n\n\n\n
[1] ObEpi-Roche 2020 \u2013 National obesity survey in France. [2] Aster\u00e8s 2024 \u2013 Obesity in France: current cost and 2030 projections. [3] Wilding JPH et al. NEJM 2021 \u2013 STEP-1 trial, semaglutide 2.4mg. [4] Jastreboff AM et al. NEJM 2022 \u2013 SURMOUNT-1 trial, tirzepatide. [5] NEJM 2023 \u2013 Retatrutide Phase 2 results. [6] ADA 2025, Lancet (submitted) \u2013 CagriSema REDEFINE. [7] Lilly \u2013 Orforglipron Phase 3 ATTAIN 2024\u201325. [8] ACTION-FRANCE 2023 \u2013 Patient survey (J Clin Med). [9] DGOS 2023 \u2013 Report on Specialized Obesity Centers. [10] HAS\/CEPS 2024 \u2013 Notes on Wegovy and reimbursement. [11] US RWE 2023\u201324 \u2013 GLP-1 adherence data. [12] FFO 2022 \u2013 Psychological follow-up report, CSO. [13] OECD 2023 \u2013 The Heavy Burden of Obesity. [14] US real-world data, IQVIA 2024. [15] Danish Ministry of Health 2023 \u2013 National obesity strategy. [16] Fauci A. et al. \u2013 HIV, success of triple therapy (1990s)<\/p>\n\n\n\n
Obesity has become a major public health issue in France. It currently affects more than 8 million individuals, and prevalence continues to rise. Projections estimate that nearly 20 million French citizens could be living with obesity by 2030 [1]. Once regarded merely as a lifestyle concern, obesity is now recognized as a complex chronic disease. […]<\/p>\n","protected":false},"author":4,"featured_media":8717,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_seopress_robots_primary_cat":"none","_seopress_titles_title":"","_seopress_titles_desc":"Obesity in France is rising fast. Explore GLP-1 breakthroughs, care gaps, reimbursement challenges, and what\u2019s next for patients and pharma.","_seopress_robots_index":"","content-type":"","footnotes":""},"categories":[80],"tags":[],"class_list":{"0":"post-8714","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-views"},"acf":[],"_links":{"self":[{"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/posts\/8714","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/comments?post=8714"}],"version-history":[{"count":0,"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/posts\/8714\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/media\/8717"}],"wp:attachment":[{"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/media?parent=8714"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/categories?post=8714"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.aplusaresearch.com\/fr\/wp-json\/wp\/v2\/tags?post=8714"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"\"](\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2025\/10\/prevalence-of-overweight-and-obesity-in-france-\u2013-obepi-roche-2020-1.webp\")
<\/figure>\n<\/div>\n\n\n\n![\"\"](\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2025\/10\/weight-loss-efficacy-pivotal-trials-phases-2-3-approximate-ranges-3-7.webp\")
<\/figure>\n<\/div>\n\n\n\n\n![\"\"](\"https:\/\/www.aplusaresearch.com\/wp-content\/uploads\/2025\/10\/cost-of-obesity-in-france-asteres-2024-2030-projection-2.webp\")
<\/figure>\n<\/div>\n\n\n\n\n